{"id":192286,"name":"INTELLIA THERAPEUTICS","slug":"intellia-therapeutics","state":"MA","country":"United States of America","description":"biotechnology company","totalSpending":390000,"filings":13,"yearlySpending":[{"year":2019,"income":70000},{"year":2020,"income":200000},{"year":2021,"income":120000},{"year":2022,"income":0}],"issues":["HCR"],"firms":["CROSSROADS STRATEGIES, LLC"],"lobbyists":["KATHERINE DAPPER","MATHEW LAPINSKI","MARC NUMEDAHL","JASON VAN PELT","JASON GLEASON","SHAY HANCOCK","BRITTANY HERNANDEZ"],"govEntities":["Executive Office of the President (EOP)","HOUSE OF REPRESENTATIVES","Office of the Vice President of the United States","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["Education and advocacy related to gene therapy.","Education and advocacy related to gene therapy.","Education and advocacy related to gene therapy;\nH.R.3, Lower Drug Costs Now Act of 2019;\nS.2543, Prescription Drug Pricing Reduction Act of 2019;\nH.R.19, Lower Costs, More Cures Act of 2019.","Education and advocacy related to gene therapy.\nEducation around COVID-19 therapies.\nH.R.3, Lower Drug Costs Now Act of 2019. \nS.2543, Prescription Drug Pricing Reduction Act of 2019. \nH.R.19, Lower C","Education and advocacy related to gene therapy.\nEducation around COVID-19 therapies.\nH.R.3, Lower Drug Costs Now Act of 2019. \nS.2543, Prescription Drug Pricing Reduction Act of 2019. \nH.R.19, Lower C"],"years":[2019,2020,2021,2022]}